- Advertise
- About OncLive
- Editorial Board
- CancerNetwork.com
- CGTlive.com
- CureToday.com
- OncNursingNews.com
- TargetedOnc.com
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Baylor Scott & White Charles A. Sammons Cancer Center | Strategic Alliance Partners
Baylor Scott & White Charles A. Sammons Cancer Center – Dallas and Baylor Scott & White T. Boone Pickens Cancer Hospital make up one of the largest cancer treatment centers in the U.S. As a destination cancer center in immunotherapy and backed by the resources of Texas’ largest not-for-profit healthcare system, we offer innovative, comprehensive and personalized cancer care plans tailored to each patient’s unique needs. From highly specialized programs based on type of cancer to forward-thinking clinical trials to a holistic approach to healing, we are with our patients along every step of their journey no matter how challenging the road becomes.
Latest from Baylor Scott & White Charles A. Sammons Cancer Center
Anticipating Key Studies and Pipeline Treatments in mCRC Landscape
April 11, 2024
Video
The experts provide their final thoughts surrounding the impact of prospective trials and therapy regimens for treating patients with refractory mCRC.
Unmet Needs Surrounding mCRC Treatment
April 11, 2024
Video
Key opportunities to improve the mCRC treatment landscape are illustrated by the expert panelists.
Data Surrounding Treatment for MSI-high Patients from ASCO 2024
April 04, 2024
Video
Dr Kim offers key perspective for MSI-high patients based on data presented at ASCO 2024.
Real-World Data Surrounding Sequencing Strategies for Refractory mCRC
April 04, 2024
Video
Multiple abstracts from ESMO 2023, including a focus on tumor location, are highlighted.
Treatment Sequencing for Refractory mCRC and SUNLIGHT Study Analysis
March 28, 2024
Video
Data presented at ESMO 2023 and ASCO GI 2024 highlight the impact of prior therapy, including VEGF inhibitors or fluoropyrimidine, on mCRC treatment approach.
Considerations for Platinum-based Therapy
March 28, 2024
Video
Key factors, particularly neuropathy, drive the discussion for platinum-based therapy for patients with non-refractory mCRC.
Identifying Ideal Candidates for Triplet Therapy in mCRC Treatment
March 21, 2024
Video
Considerations for patients to receive aggressive mCRC therapy regimens are navigated by the panelists.
Fatigue Associated with Bevacizumab, Fruquintinib, TAS-102 Therapies
March 21, 2024
Video
Side effect profiles driven by fruquintinib use are discussed.
Consideration for Fruquintinib Dosing and Titration
March 14, 2024
Video
Mark A Lewis, MD, and Scott Paulson, MD, share their experiences utilizing fruquintinib.
Utilizing RWE to Derive Optimal Treatment Strategy for Refractory mCRC
March 14, 2024
Video
Richard Kim, MD, discusses the significance of real-world evidence when selecting treatment sequencing strategy.
Dose Modifications and Tolerability Associated with mCRC Treatment Regimens
March 07, 2024
Video
Managing dose adjustments and tolerability in metastatic colorectal cancer (mCRC) treatment regimens for optimal efficacy is underscored.
FRESCO-2 Study Highlights
March 07, 2024
Video
Medical experts provide key takeaways and impacts from the FRESCO-2 study.
Compounding Impact of TAS-102 and Bevacizumab in mCRC Treatment
February 29, 2024
Video
Marwan G Fakih, MD, drives a discussion highlighting a significant combination therapy in mCRC treatment.
Fruquintinib MoA and Toxicity Profile Overview
February 29, 2024
Video
Key safety considerations for the use of fruquintinib are explored.
Evaluating 3L Treatment Landscape Evolution
February 22, 2024
Video
Dr Parikh drives a conversation surrounding 3L treatment for patients diagnosed with metastatic colorectal cancer.
Overview of Current mCRC Treatment Landscape
February 22, 2024
Video
Medical experts open a discussion providing an update on the current impact of metastatic colorectal cancer and common treatment strategies.
Dr Abushahin on Biomarker Testing in mCRC
July 13, 2023
Video
Laith Abushahin, MD, discusses the evolution of targeted therapy for patients with metastatic colorectal cancer and the importance of biomarker testing in this patient population.
O’Shaughnessy Showcases Highlights in Breast Cancer Guiding 2023 IBC Congresses
April 21, 2023
Article
Joyce A. O’Shaughnessy, MD, highlights multidisciplinary approaches including discussions on tumor boards, and discusses how to better assist patients with accessing care, and notable advances in the field particularly with the HER2 classification.
Dr Christensen on the Influence of Patient Selection for BCL-2 Inhibitor Treatment in AML
April 14, 2023
Video
Bradley W. Christensen, MD, discusses the process of patient selection for BCL-2 induction therapy in patients with acute myeloid leukemia in accordance with their individual disease characteristics.
Dr O’Shaughnessy on Real-World Data for Tucatinib-Based Therapy in HER2+ Breast Cancer
April 11, 2023
Video
Joyce A. O’Shaughnessy, MD, discusses real-world data for the use of the phase 2 HER2CLIMB trial regimen of tucatinib plus trastuzumab and capecitabine in HER2-positive breast cancer.